Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis

Background Multi-criteria decision analysis (MCDA) was proposed to surmount arbitrary clinical decisions in the field of biological therapies for psoriatic patients. At the same time, MCDA may further highlight the potential of bimekizumab for the treatment of moderate-to-severe psoriasis, compared...

Full description

Bibliographic Details
Authors: Zozaya, Neboa, Abdalla, Fernando, Zamora, Santiago Alfonso, Balea Filgueiras, Jesús, Carrascosa Carrillo, José Manuel, Delgado Sánchez, Olga, Dolz Sinisterra, Francisco, Garcia-Ruiz, Antonio, Pinto, Pedro Herranz, Manfredi, Antonio, Olmos, Jose Martinez, Morales de Los Ríos Luna, Paloma, Puig, Lluis, Ros, Sandra, HIdalgo-Vega, Alvaro
Format: article
Publication Date:2022
Country:España
Institution:Conselleria de Salut i Consum del Govern de les Illes Balears
Repository:Docusalut
Language:English
OAI Identifier:oai:docusalut.com:20.500.13003/19450
Online Access:https://hdl.handle.net/20.500.13003/19450
Access Level:Open access
Keyword:Psoriasis
Adalimumab
Severity of Illness Index
Treatment Outcome
Humans
Antibodies, Monoclonal, Humanized
Decision Support Techniques
Resultado del Tratamiento
Técnicas de Apoyo para la Decisión
Humanos
Índice de Severidad de la Enfermedad
Anticuerpos Monoclonales Humanizados
moderate-to-severe
biologics
multi-criteria decision analysis
MCDA
bimekizumab
id ES_f40047909d6747988fdba32cbf4a4e21
oai_identifier_str oai:docusalut.com:20.500.13003/19450
network_acronym_str ES
network_name_str España
repository_id_str
spelling Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysisZozaya, NeboaAbdalla, FernandoZamora, Santiago AlfonsoBalea Filgueiras, JesúsCarrascosa Carrillo, José ManuelDelgado Sánchez, OlgaDolz Sinisterra, FranciscoGarcia-Ruiz, AntonioPinto, Pedro HerranzManfredi, AntonioOlmos, Jose MartinezMorales de Los Ríos Luna, PalomaPuig, LluisRos, SandraHIdalgo-Vega, AlvaroPsoriasisAdalimumabSeverity of Illness IndexTreatment OutcomeHumansAntibodies, Monoclonal, HumanizedDecision Support TechniquesAdalimumabResultado del TratamientoTécnicas de Apoyo para la DecisiónHumanosPsoriasisÍndice de Severidad de la EnfermedadAnticuerpos Monoclonales HumanizadosPsoriasismoderate-to-severebiologicsmulti-criteria decision analysisMCDAbimekizumabBackground Multi-criteria decision analysis (MCDA) was proposed to surmount arbitrary clinical decisions in the field of biological therapies for psoriatic patients. At the same time, MCDA may further highlight the potential of bimekizumab for the treatment of moderate-to-severe psoriasis, compared to placebo, adalimumab, ustekinumab, secukinumab, and even ixekizumab and risankizumab. Research design and methods The EVIDEM framework was adapted to reflect relevant criteria for the assessment. Estimated values were obtained by means of an additive linear model combining weights and scores assigned by a multidisciplinary committee of 12 experts. Consistency and replicability were evaluated through an alternative weighting method and a re-test. Results Bimekizumab was assessed by the committee as an intervention with a positive value contribution for the treatment of moderate-to-severe psoriasis in comparison to any of the alternatives. The drug provides a substantial therapeutical benefits and improves the health results reported by the patients, as it combines a higher level of clearance, rapidity, and persistence with a similar safety and tolerability profile. Conclusions Under a methodology with increasing use in the health field, bimekizumab was evaluated as a drug with a high added value for the treatment of moderate-to-severe psoriasis when compared to six different alternatives.Taylor & Francis Ltd20222022-09-0120222022-09-01research articlehttp://purl.org/coar/resource_type/c_2df8fbb1info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/20.500.13003/19450reponame:Docusalutinstname:Conselleria de Salut i Consum del Govern de les Illes BalearsInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Attribution-NonCommercial 4.0 Internationalhttp://creativecommons.org/licenses/by-nc/4.0/info:eu-repo/semantics/openAccessoai:docusalut.com:20.500.13003/194502026-06-22T12:44:07Z
dc.title.none.fl_str_mv Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis
title Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis
spellingShingle Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis
Zozaya, Neboa
Psoriasis
Adalimumab
Severity of Illness Index
Treatment Outcome
Humans
Antibodies, Monoclonal, Humanized
Decision Support Techniques
Adalimumab
Resultado del Tratamiento
Técnicas de Apoyo para la Decisión
Humanos
Psoriasis
Índice de Severidad de la Enfermedad
Anticuerpos Monoclonales Humanizados
Psoriasis
moderate-to-severe
biologics
multi-criteria decision analysis
MCDA
bimekizumab
title_short Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis
title_full Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis
title_fullStr Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis
title_full_unstemmed Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis
title_sort Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis
dc.creator.none.fl_str_mv Zozaya, Neboa
Abdalla, Fernando
Zamora, Santiago Alfonso
Balea Filgueiras, Jesús
Carrascosa Carrillo, José Manuel
Delgado Sánchez, Olga
Dolz Sinisterra, Francisco
Garcia-Ruiz, Antonio
Pinto, Pedro Herranz
Manfredi, Antonio
Olmos, Jose Martinez
Morales de Los Ríos Luna, Paloma
Puig, Lluis
Ros, Sandra
HIdalgo-Vega, Alvaro
author Zozaya, Neboa
author_facet Zozaya, Neboa
Abdalla, Fernando
Zamora, Santiago Alfonso
Balea Filgueiras, Jesús
Carrascosa Carrillo, José Manuel
Delgado Sánchez, Olga
Dolz Sinisterra, Francisco
Garcia-Ruiz, Antonio
Pinto, Pedro Herranz
Manfredi, Antonio
Olmos, Jose Martinez
Morales de Los Ríos Luna, Paloma
Puig, Lluis
Ros, Sandra
HIdalgo-Vega, Alvaro
author_role author
author2 Abdalla, Fernando
Zamora, Santiago Alfonso
Balea Filgueiras, Jesús
Carrascosa Carrillo, José Manuel
Delgado Sánchez, Olga
Dolz Sinisterra, Francisco
Garcia-Ruiz, Antonio
Pinto, Pedro Herranz
Manfredi, Antonio
Olmos, Jose Martinez
Morales de Los Ríos Luna, Paloma
Puig, Lluis
Ros, Sandra
HIdalgo-Vega, Alvaro
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv
dc.subject.none.fl_str_mv Psoriasis
Adalimumab
Severity of Illness Index
Treatment Outcome
Humans
Antibodies, Monoclonal, Humanized
Decision Support Techniques
Adalimumab
Resultado del Tratamiento
Técnicas de Apoyo para la Decisión
Humanos
Psoriasis
Índice de Severidad de la Enfermedad
Anticuerpos Monoclonales Humanizados
Psoriasis
moderate-to-severe
biologics
multi-criteria decision analysis
MCDA
bimekizumab
topic Psoriasis
Adalimumab
Severity of Illness Index
Treatment Outcome
Humans
Antibodies, Monoclonal, Humanized
Decision Support Techniques
Adalimumab
Resultado del Tratamiento
Técnicas de Apoyo para la Decisión
Humanos
Psoriasis
Índice de Severidad de la Enfermedad
Anticuerpos Monoclonales Humanizados
Psoriasis
moderate-to-severe
biologics
multi-criteria decision analysis
MCDA
bimekizumab
description Background Multi-criteria decision analysis (MCDA) was proposed to surmount arbitrary clinical decisions in the field of biological therapies for psoriatic patients. At the same time, MCDA may further highlight the potential of bimekizumab for the treatment of moderate-to-severe psoriasis, compared to placebo, adalimumab, ustekinumab, secukinumab, and even ixekizumab and risankizumab. Research design and methods The EVIDEM framework was adapted to reflect relevant criteria for the assessment. Estimated values were obtained by means of an additive linear model combining weights and scores assigned by a multidisciplinary committee of 12 experts. Consistency and replicability were evaluated through an alternative weighting method and a re-test. Results Bimekizumab was assessed by the committee as an intervention with a positive value contribution for the treatment of moderate-to-severe psoriasis in comparison to any of the alternatives. The drug provides a substantial therapeutical benefits and improves the health results reported by the patients, as it combines a higher level of clearance, rapidity, and persistence with a similar safety and tolerability profile. Conclusions Under a methodology with increasing use in the health field, bimekizumab was evaluated as a drug with a high added value for the treatment of moderate-to-severe psoriasis when compared to six different alternatives.
publishDate 2022
dc.date.none.fl_str_mv 2022
2022-09-01
2022
2022-09-01
dc.type.none.fl_str_mv research article
http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://hdl.handle.net/20.500.13003/19450
url https://hdl.handle.net/20.500.13003/19450
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution-NonCommercial 4.0 International
http://creativecommons.org/licenses/by-nc/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution-NonCommercial 4.0 International
http://creativecommons.org/licenses/by-nc/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Taylor & Francis Ltd
publisher.none.fl_str_mv Taylor & Francis Ltd
dc.source.none.fl_str_mv reponame:Docusalut
instname:Conselleria de Salut i Consum del Govern de les Illes Balears
instname_str Conselleria de Salut i Consum del Govern de les Illes Balears
reponame_str Docusalut
collection Docusalut
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869424431039774720
score 15,81155

Similar Items